Keap1 antibody

Sorafenib was obtained from LC laboratories (ref. no. S8502). Lenvatinib was purchased from Selleck Chemicals (ref. no. S1164). 2’7’-dichlorodihydrofluorescein diacetate (H2DCFDA), H₂O₂ solution and menadione were purchased from Sigma (ref. no. D6883, H1009, and M2518). Lipofectamine 2000 reagent and sulforaphane were obtained from Invitrogen (ref. no. 11668019) and Enzo Life Science (ref. no. ALX-350-230-M010), respectively. SDS (20%) was obtained from Fisher bioreagents (ref. no. bp1311-1). Nrf2 antibody and KEAP1 antibody were purchased from Abcam (ab62352) and Cell Signaling (#8047S), respectively.

The human pancreatic cancer cell lines PANC-1 and CFPAC-1 used in our study were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and stably cultured, passaged, and cryopreserved in our laboratory. Basic Dulbecco's modified Eagle's medium (DMEM, Gibco, USA) with 10% fetal bovine serum (FBS, Sigma, St. Louis, MO, USA) was utilized to culture PANC-1 cells, while basic RPMI-1640 medium (Gibco, USA) with 10% FBS (Sigma, St. Louis, MO, USA) was utilized to culture CFPAC-1 cells, which were cultured in an incubator at 37°C, 5% CO₂, and 95% humidity. The drug curcumin was purchased from MedChemExpress (MCE, New Jersey, USA). The anti-sestrin2 antibody was purchased from Proteintech (Chicago, USA), while the anti-Nrf2 antibody, p-Nrf2 antibody, Keap1 antibody, HO-1 antibody, and NQO-1 antibody were purchased from Abcam (Britain).